West Pharmaceutical Services stock attracts analyst coverage

West Pharmaceutical Services stock is drawing analyst attention after a USD 407.56 average 12-month target was listed for the company on September 30, 2026. The medical instruments supplier also delivered USD 872.3 million in fiscal Q2 2026 revenue, giving the valuation debate a recent operating benchmark.

Analysts set targets above USD 400

Investing.com listed 16 analysts with an average 12-month target of USD 407.56 on September 30, 2026. Morgan Stanley set a USD 400.00 target on September 22, 2026, while UBS had a USD 415.00 target dated September 9, 2026.

The range shows a divided valuation picture: targets span USD 340.00 to USD 459.00, a USD 119.00 spread. The average target is USD 31.00 above the USD 376.63 primary-exchange quote available for September 29, 2026, equal to 8.24 percent.

Q2 revenue beat expectations

According to MarketBeat on September 25, 2026, West reported USD 2.37 in quarterly EPS against a USD 2.08 consensus estimate for fiscal Q2 2026. Revenue of USD 872.30 million exceeded the USD 839.98 million estimate, while sales increased 13.8 percent from the same quarter a year earlier.

Management set fiscal 2026 EPS guidance at USD 8.85-9.05 and Q3 2026 guidance at USD 2.14-2.24, according to the same MarketBeat report. The comparison between actual Q2 EPS and consensus amounts to a USD 0.29 beat, which helps explain why the latest target revisions remain above USD 400.

Stock remains near its yearly high

West Pharmaceutical Services was last at USD 376.63 on the NYSE on September 29, 2026 at 4:01 p.m. ET. Its 52-week range was USD 223.83 to USD 386.00, placing the quote 2.43 percent below the high, while market capitalization stood at USD 26.5 billion.

More news and analysis on West Pharmaceutical Services stock